Moving to the promoter methylation level assessment, almost all of the analyzed tumors with a significant score (p-value < 0.05) demonstrated hypermethylation of CDKN2A under tumor conditions in comparison to normal samples (Figure 6B). The gene discussed is CDKN2A; the disease is neoplasm.